- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial appeared first on ALIGOS Therapeutics.
The post Synergistic fat mass loss in diet-induced obese mice when thyroid hormone receptor-β agonist ALG-055009 was administered in combination with incretin receptor agonists appeared first on ALIGOS Therapeutics.
The post The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities appeared first on ALIGOS Therapeutics.
The post ALG-001075, the parent of pevifoscorvir sodium, exhibits potent in vitro antiviral properties compared to other HBV capsid assembly modulators in clinical development appeared first on ALIGOS Therapeutics.
The post Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cell-based experiments appeared first on ALIGOS Therapeutics.
The post Antisense oligonucleotide-based strategy to target hepatitis delta virus infections appeared first on ALIGOS Therapeutics.
The post Discovery of novel HDV entry inhibitors with selectivity over bile acid inhibition appeared first on ALIGOS Therapeutics.
The post Preclinical characterization of ALG-093940, a potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor for the treatment of chronic hepatitis B infection and liver cancer appeared first on ALIGOS Therapeutics.
The post Pevifoscorvir sodium demonstrated profound antiviral activity in untreated HBeAg+ subjects, regardless of baseline ALT level appeared first on ALIGOS Therapeutics.
The post Population pharmacokinetics of pevifoscorvir sodium (ALG-000184) in healthy participants and participants with chronic hepatitis B in support of phase 2 dose selection appeared first on ALIGOS Therapeutics.